TITLE

Serum-based ALYGNSA immunoassay for the prostate cancer biomarker, total prostate-specific antigen (tPSA)

AUTHOR(S)
Mackness, Brian C.; McDonald, Melisenda J.
PUB. DATE
August 2010
SOURCE
Analytical & Bioanalytical Chemistry;Aug2010, Vol. 397 Issue 7, p3151
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Prostate-specific antigen (PSA) is a serum glycoprotein overproduced by the prostate in prostate cancer (≥4 ng/mL in the bloodstream). An immunoassay for total PSA ( tPSA) was developed using the ALYGNSA method to enhance capture antibody orientation and a limit of detection of 0.63 ng/mL was reported, a limit 15-fold lower than a commercial tPSA ELISA assay. This ALYGNSA assay, however, was performed using only buffer-based proteins and blocking agents (Mackness et al., Anal Bioanal Chem 396:681–686, ). To improve the clinical application of this system, a serum-based tPSA ALYGNSA was developed employing human serum. This assay also resulted in a limit of detection of 0.63 ng/mL of tPSA protein. The findings reported here provide support for the clinical application of this assay for diagnosis, progression, treatment, and possible recurrence of prostate cancer.
ACCESSION #
52299521

 

Related Articles

  • Macrophage Inhibitory Cytokine 1 Biomarker Serum Immunoassay in Combination with PSA Is a More Specific Diagnostic Tool for Detection of Prostate Cancer. Li, Ji; Veltri, Robert W.; Yuan, Zhen; Christudass, Christhunesa S.; Mandecki, Wlodek // PLoS ONE;Apr2015, Vol. 10 Issue 4, p1 

    Background: Prostate cancer (PCa) is the most common malignancy among men in the United States. Though highly sensitive, the often-used prostate-specific antigen (PSA) test has low specificity which leads to overdiagnosis and overtreatment of PCa. This paper presents results of a retrospective...

  • Multiplex Biomarker Approach for Determining Risk of Prostate-Specific Antigen-Defined Recurrence of Prostate Cancer. Rhodes, Daniel R.; Sanda, Martin G.; Otte, Arie P.; Chinnaiyan, Arul M.; Rubin, Mark A. // JNCI: Journal of the National Cancer Institute;5/7/2003, Vol. 95 Issue 9, p661 

    Background: Molecular signatures in cancer tissue may be useful for diagnosis and are associated with survival. We used results from high-density tissue microarrays (TMAs) to define combinations of candidate biomarkers associated with the rate of prostate cancer progression after radical...

  • Update on Prostate-Specific Antigen Testing for the Early Detection of Prostate Cancer. John Terrell; Claus Roehrborn; Frank Wians; Pierre Karakiewicz // Laboratory Medicine;Oct2008, Vol. 39 Issue 10, p613 

    The introduction of prostate-specific antigen (PSA) has revolutionized the detection and management of men with prostate cancer (PCa). This review discusses the clinically useful risk factors associated with the development of PCa and the salient features of PSA. It will help to highlight the...

  • Prostate specific antigen for early detection of prostate cancer: longitudinal study. Holmström, Benny; Johansson, Mattias; Bergh, Anders; Stenman, Ulf-Häkan; Halmans, Göran; Stattin, Par // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;10/3/2009, Vol. 339 Issue 7724, p793 

    The article presents a study which examined whether prostate specific antigen test attains validity standards required for prostate cancer screening. Incident cases of prostate cancer and controls matched for age and date of blood draw within the Västerbotten Intervention Project cohort in...

  • Evolving Role of Bone Biomarkers in Castration-Resistant Prostate Cancer. Brown, Janet E.; Sim, Sheryl // Neoplasia;Sep2010, Vol. 12 Issue 9, p685 

    The preferential metastasis of prostate cancer cells to bone disrupts the process of bone remodeling and results in lesions that cause significant pain and patient morbidity. Although prostate-specific antigen (PSA) is an established biomarker in prostate cancer, it provides only limited...

  • A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. Vickers, Andrew J.; Cronin, Angel M.; Aus, Gunnar; Pihl, Carl-Gustav; Becker, Charlotte; Pettersson, Kim; Scardino, Peter T.; Hugosson, Jonas; Lilja, Hans // BMC Medicine;2008, Vol. 6, Special section p1 

    Background: Prostate-specific antigen (PSA) is widely used to detect prostate cancer. The low positive predictive value of elevated PSA results in large numbers of unnecessary prostate biopsies. We set out to determine whether a multivariable model including four kallikrein forms (total, free,...

  • CLINICAL SIGNIFICANCE OF SERUM PSA (PROSTATE SPECIFIC ANTIGEN) IN TREATMENT OF PROSTATE CANCER. S. R. KANKONKAR; S. V. JOSHI; E. SOARES // Medical Case Reports;2013, Vol. 4 Issue 1, p44 

    Prostate specific antigen (PSA) has been described as a single test with highest positive predictive value for diagnosing carcinoma of prostate. Routine use of PSA helps in diagnosing organ-confined prostate cancers. Monitoring the evolution of prostate cancer has crucial importance since this...

  • Valoarea predictivea si validitatea PSA, FREE PSAsi a examenului clinic local in identificarea cancerului de prostatea. Iordache, A.; Surcel, C.; Furtunescu, Florentina; Stoica, R.; Gingu, C.; Cerempei, V.; Mirvald, C.; Sinescu, I. // Romanian Journal of Urology;Dec2011, Vol. 10 Issue 4, p47 

    Scientific context: Prostate cancer is the most common noncutaneous cancer and represents the second cause of mortality through neoplasia in United States and the EU. In Romania the incidence varies according to age, range from 6-151 per 100,000 people, reaching a maximum at the age group 70-74...

  • New marker may be more specific for prostate Ca. Dosa, Laszlo // Urology Times;May2007, Vol. 35 Issue 5, p1 

    The article informs that the discovery of prostate-specific antigen (PSA) has brought a sharp change in the profile of the prostate cancer population. Doctor Robert Getzenberg and colleagues say that PSA has many significant limitations and so they have developed a new serum biomarker known as...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics